Hikma rolls out Ganciclovir
Ganciclovir for injection had a market value of roughly $8 million for the 12 months ended April 2021, according to IQVIA.
Hikma is introducing ganciclovir for injection in a dosage strength of 500 mg.
The product is indicated for the treatment of cytomegalovirus retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome, and for the prevention of CMV disease in adult transplant recipients at risk for CMV disease.
Ganciclovir for injection had a market value of roughly $8 million in the 12 months ending April 2021, according to IQVIA.